Limited data exist regarding the role of CDK4/6 and cyclin D1 interaction in the development of palbociclib resistance, and effective targets for palbociclib-resistant ER+ and ER− breast cancers are largely unknown. This evidence concerns the gene CDK4 and breast cancer.